FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

仅供研究使用。 完整免责声明 →

研究/FDA Extends Pharmacy Compounding Advisory Committee’s Charter for Peptide Research and Patient Safety
返回研究图书馆

FDA Extends Pharmacy Compounding Advisory Committee’s Charter for Peptide Research and Patient Safety

May 25, 2026
Share
新兴研究

基于新兴研究。这些发现很有前景,但需要进一步验证。

关于此分析

本文是基于最近发布的新闻或临床试验公告的人工智能辅助摘要。旨在为肽类研究社区提供快速、易懂的概览。欲获得完整准确性,请参阅下方提供的原始来源。

FDA Extends Pharmacy Compounding Advisory Committee’s Charter for Peptide Research and Patient Safety

The Food and Drug Administration (FDA) has announced a significant move to ensure ongoing oversight of pharmacy compounding, an important area that affects peptide research and patient safety. The renewal of the Pharmacy Compounding Advisory Committee signals the agency's commitment to maintaining stringent standards in this critical sector.

Background

Pharmacy compounding is the process by which pharmacists create customized medications tailored to individual patients' needs. This practice can be particularly crucial for peptides, as these molecules often require precise formulations and dosing that may not be available through conventional pharmaceutical products. The Pharmacy Compounding Advisory Committee plays a vital role in advising the FDA on issues related to compounding pharmacies, including quality control measures, compliance with federal regulations, and patient safety protocols.

For researchers working with peptide therapies, this committee ensures that the unique challenges of manufacturing these complex molecules are addressed appropriately. Peptides are increasingly being used in various medical applications due to their specificity and effectiveness in treating conditions such as diabetes, cancer, and autoimmune diseases. Ensuring proper oversight through the renewal of the advisory committee helps maintain high standards for compounding practices.

Key Details

The FDA's decision to extend the charter of the Pharmacy Compounding Advisory Committee is a crucial step toward continuing its mandate beyond its initial expiration date in 2026. The renewed charter will be valid until April 25, 2028, providing continuity and stability for those involved in compounding practices.

This action underscores the importance of ongoing collaboration between regulatory bodies like the FDA and stakeholders in the pharmaceutical industry. It also highlights the agency's recognition that pharmacy compounding remains a vital part of healthcare delivery systems, especially as new therapeutic options emerge from peptide research.

Key Takeaways

  • Committee Renewal: The Pharmacy Compounding Advisory Committee has been renewed for an additional two years by the FDA.
  • Public Interest Focus: The decision was made in recognition of public interest and the importance of maintaining high standards for compounded medications.
  • Impact on Peptides: This renewal will directly impact the production and regulation of peptides, ensuring they are manufactured safely and effectively.
  • Regulatory Continuity: The extension provides regulatory continuity and stability for those involved in pharmacy compounding practices.

What This Means

The extension of the Pharmacy Compounding Advisory Committee's charter is a positive development for researchers, clinicians, and informed consumers working with peptide therapies. It signifies that the FDA remains vigilant about ensuring safety and quality standards in compounded medications, which are often highly specialized and tailored to individual patient needs. For the peptide community, this means continued support from regulatory bodies as they develop new treatments and refine existing ones.

---

Source: Federal Register — Published 2026-04-30

This article is for informational purposes only and does not constitute medical advice.

编辑注释

此分析使用人工智能工具生成,并由Peptide Contacts编辑团队审核。尽管我们力求准确,但人工智能生成的内容可能包含错误或遗漏。鼓励读者查阅 原始来源 以获取完整细节、方法和数据。

Peptide Contacts提供研究摘要仅供信息参考之用。此内容不构成医疗建议。在做出任何健康决策前,请咨询合格的医疗服务提供者。

Comments

Sign in to join the discussion

本文由人工智能生成,可能存在不准确之处。仅供信息参考之用,并不构成医疗建议。请务必通过原始来源核实信息并在做出任何健康决策前咨询合格的医疗服务提供者。